NCT01098344View on ClinicalTrials.gov

MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Pancreatic Cancer
Interventions
DRUG

Notch signaling pathway inhibitor MK0752

DRUG

gemcitabine hydrochloride

OTHER

imaging biomarker analysis

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

Trial Locations (5)

CB2 2QQ

Addenbrooke's Hospital, Cambridge

LE1 5WW

Leicester Royal Infirmary, Leicester

EC1M 6BQ

Barts and the London School of Medicine, London

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

L59 7TF

St James' Hospital, Leeds

Sponsors

Lead Sponsor

Cancer Research UK
All Listed Sponsors
lead

Cancer Research UK

OTHER

NCT01098344 - MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter